BlueCross BlueShield Federal Employee Program.

# ILARIS
# PRIOR APPROVAL REQUEST

**Send completed form to:**
**Service Benefit Plan**
**Prior Approval**
**P.O. Box 52080 MC 139**
**Phoenix, AZ 85072-2080**
**Attn. Clinical Services**
**Fax: 1-877-378-4727**

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

| **Patient Information (required)** | | | **Provider Information (required)** | | |
|---|---|---|---|---|---|
| Date: | | | Provider Name: | | |
| Patient Name: | | | Specialty: | NPI: | |
| Date of Birth: | Sex: ❑Male ❑Female | | Office Phone: | Office Fax: | |
| Street Address: | | | Office Street Address: | | |
| City: | State: | Zip: | City: | State: | Zip: |
| Patient ID: **R** | | | Physician Signature: | | |
| **PHYSICIAN COMPLETES** | | | | | |

## Ilaris (canakinumab)

****Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit**

**NOTE:** Form must be completed in its **entirety** for processing

Is this request for brand or generic? ❑Brand ❑Generic

1. What is the patient's diagnosis?

❑Cryopyrin-Associated Periodic Syndromes (CAPS) ❑Familial Mediterranean Fever (FMF)
❑Familial Cold Auto-inflammatory Syndrome (FCAS) ❑Muckle-Wells Syndrome (MWS)
❑Hyperimmunoglobulin D Syndrome (HIDS) / Mevalonate Kinase Deficiency (MKD)
❑Tumor necrosis factor Receptor Associated Periodic Syndrome (TRAPS)
❑Gout flares

a. Has the patient been on Ilaris continuously for the last **6 months**, excluding samples? ❑Yes ❑No*****

❑**NO** – this is **INITIATION** of therapy, please answer the following question:
i. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to NSAIDs and colchicine? ❑Yes ❑No
ii. Are repeat courses of corticosteroids appropriate for the patient? ❑Yes ❑No

❑**YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:
i. Has the patient's condition improved or stabilized while on Ilaris? ❑Yes ❑No

❑Still's disease, including Adult-Onset Still's Disease (AOSD)

a. Has the patient been on Ilaris continuously for the last **6 months**, excluding samples? ***Please select answer below:***

❑**NO** – this is **INITIATION** of therapy, please answer the following question:
i. Is the patient's condition considered to be active? ❑Yes ❑No

❑**YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:
i. Has the patient's condition improved or stabilized while on Ilaris? ❑Yes ❑No

❑Systemic Juvenile Idiopathic Arthritis (SJIA)

a. Has the patient been on Ilaris continuously for the last **6 months**, excluding samples? ***Please select answer below:***

❑**NO** – this is **INITIATION** of therapy, please answer the following question:
i. Is the patient's condition considered to be active? ❑Yes ❑No

❑**YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:
i. Has the patient's condition improved or stabilized while on Ilaris? ❑Yes ❑No

❑Other diagnosis (***please specify***): _____

2. Does the patient have any evidence of an active infection requiring medical intervention? ❑Yes ❑No
3. Will Ilaris be used in combination with a tumor necrosis factor (TNF) antagonist (e.g., Cimzia, Enbrel, Humira, Remicade, Simponi)? ❑Yes***** ❑No

****If YES***, please specify the medication: _____

4. Will Ilaris be used in combination with another interleukin-1 receptor antagonist (e.g., Arcalyst, Kineret)? ❑Yes***** ❑No

****If YES***, please specify the medication: _____

The information provided on this form will be used to determine the provision of healthcare benefits under a U.S. federal government program, and any falsification of records may subject the provider to prosecution, either civilly or criminally, under the False Claim Acts, the False Statements Act, the mail or wire fraud statutes, or other federal or state laws prohibiting such falsification. **Prescriber Certification:** I certify all information provided on this form to be true and correct to the best of my knowledge and belief. I understand that the insurer may request a medical record if the information provided herein is not sufficient to make a benefit determination or requires clarification and I agree to provide any such information to the insurer. Ilaris – FEP MD Fax Form Revised 10/20/2023

BlueCross BlueShield Federal Employee Program.

**ILARIS**
**PRIOR APPROVAL REQUEST**

**Send completed form to:**
**Service Benefit Plan**
**Prior Approval**
**P.O. Box 52080 MC 139**
**Phoenix, AZ 85072-2080**
**Attn. Clinical Services**
**Fax: 1-877-378-4727**

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

| | |
|---|---|
| **Electronically Online** (ePA) Results in 2-3 **minutes** **FASTEST AND EASIEST** | Now you can get responses to drug Prior Authorization requests **securely** online. **Online** submissions may receive **instant** responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to **Caremark.com/ePA.** |
| **Phone** (4-5 **minutes** for response) | The FEP Clinical Call Center can be reached at **(877)-727-3784** between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes. |
| **Fax** (3-5 **days** for response) | Fax the attached form to **(877)-378-4727**. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. ***Please only fax the completed form once as duplicate submissions may delay processing times.*** |